Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 845-857

  Wilson, Peter M ^a   Labonte, Melissa J ^b   Martin, Shelby C ^b   Kuwahara, Stephanie T ^b   El Khoueiry, Anthony ^a   Lenz, Heinz Josef ^a   Ladner, Robert D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AZUSA PACIFIC UNIVERSITY   (United States)

Author keywords

Acetylation; Colorectal; Histone deacetylase inhibitor; Panobinostat; Vorinostat

Indexed keywords

ACETYL HISTONE H3; ACETYL HISTONE H4; CASPASE 8; HISTONE DEACETYLASE; NUCLEAR PROTEIN; PANOBINOSTAT; PROTEIN P21; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MICE; NEOPLASM PROTEINS; THYMIDYLATE SYNTHASE; TIME FACTORS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880919982     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9914-7     Document Type: Article

References (50)

1. Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12:599-606
2. Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74:659-671
3. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729-26734
4. Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23
5. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458
6. Prystowsky MB, Adomako A, Smith RV, Kawachi N, McKimpson W, Atadja P et al. (2009) The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol
7. Stevens FE, Beamish H, Warrener R, Gabrielli B (2008) Histone deacetylase inhibitors induce mitotic slippage. Oncogene 27:1345-1354
8. Ishii S, Kurasawa Y, Wong J, Yu-Lee LY (2008) Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A 105:4179-4184
9. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E (2008) Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53:267-277
10. Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3:300-309
11. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC et al (2009) Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 15:3163-3171
12. Hanigan CL, Van Engeland M, De Bruine AP, Wouters KA, Weijenberg MP, Eshleman JR et al (2008) An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 135(1654-1664):e2
13. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D et al (2008) HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19:4062-4075
14. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163
15. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD (2009) DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genom 2:67
16. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202
17. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528
18. Portanova P, Russo T, Pellerito O, Calvaruso G, Giuliano M, Vento R et al (2008) The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 33:325-331
19. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003-3007
20. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210
21. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233-241
22. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society. Vol. 2009. 2010
23. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
24. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147
25. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784
26. Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD (2009) Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 125:463-473
27. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97:10014-10019
28. Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M et al (2009) A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. ASCO Meet Abs 27:4083
29. Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I et al (2009) A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 15:3189-3195
30. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S et al (2010) A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 65:979-988
31. Gold PJ, Smith DA, Iriarte D, Boatman B, Kaplan HG (2012) Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC). ASCO Meet Abs 30:582
32. Fakih MG, Groman A, McMahon J, Wilding G, Muindi JR (2012) A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 69:743-751
33. Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA et al (2010) A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 16:3786-3794
34. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR et al (2009) Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 8:782-791
35. Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ (2006) A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 840:108-115
36. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM et al (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66:181-189
37. Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L et al (2012) The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 69:555-562
38. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W et al (2010) Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance. Int J Cancer 127:2199-2208
39. Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A et al (2012) Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 106:107-115
40. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A et al (2012) Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 56:1343-1350
41. Lee SC, Cheong HJ, Kim SJ, Yoon J, Kim HJ, Kim KH et al (2011) Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines. Anticancer Res 31:3385-3394
42. Basu HS, Mahlum A, Mehraein-Ghomi F, Kegel SJ, Guo S, Peters NR et al (2011) Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol 67:705-715
43. Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S et al. (2012) Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat
44. Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ, Ladner RD (2009) Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res 37:78-95
45. Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD (2008) Novel opportunities for thymidylate metabolism as a therapeutic target. Mol Cancer Ther 7:3029-3037
46. Ladner RD, McNulty DE, Carr SA, Roberts GD, Caradonna SJ (1996) Characterization of distinct nuclear and mitochondrial forms of human deoxyuridine triphosphate nucleotidohydrolase. J Biol Chem 271:7745-7751
47. Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T et al (2010) Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer 103:1680-1691
48. Liu T, Kuljaca S, Tee A, Marshall GM (2006) Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32:157-165
49. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P et al (2010) SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 9:642-652
50. Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J et al (2011) Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer 104:756-762